Last updated: April 30, 2026
Verteporfin: Who Supplies It and What the Supply Chain Looks Like
What companies supply verteporfin for pharmaceutical and research use?
Verteporfin is a light-activated photosensitizer used in photodynamic therapy (PDT), most prominently as verteporfin in Visudyne-type products. The supply chain depends on whether the market segment is (1) branded finished product for ophthalmology (2) clinical PDT use in other indications, or (3) research-grade verteporfin for labs.
The hard supplier landscape splits into three groups:
-
Brand/marketing authorization holders for finished product (ophthalmology)
- In practice, finished-dose verteporfin is supplied through the brand channel rather than direct chemical procurement.
-
API manufacturers of verteporfin (chemical supply)
- Verteporfin API is typically sourced from specialized fine-chemical or API producers with controlled manufacturing, impurity controls, and documented regulatory packages.
-
Specialty chemical distributors and contract suppliers
- These entities sell verteporfin for research and non-commercial use, often with grade and documentation constraints relative to regulated supply.
Where does verteporfin typically come from (API vs finished product)?
Finished product distribution dominates for regulated ophthalmology use because verteporfin is dosed and administered under the brand product supply chain. In those settings, procurement typically flows through distribution networks tied to the marketing authorization.
API sourcing is common for:
- clinical manufacturing organizations supporting investigator-led trials,
- generic or follow-on development,
- contract manufacturing organizations (CMOs) formulating verteporfin into PDT products,
- research institutions that procure verteporfin as reference material.
How do supplier relationships usually work for verteporfin?
Verteporfin supply is usually structured through one of these models:
Which supplier types are relevant for R&D vs clinical manufacturing?
- R&D (small scale, method development): research-grade distributors are usually sufficient if the work does not require GMP documentation.
- Clinical manufacturing (GMP scale): customers require an API package compatible with clinical GMP expectations: defined specifications, impurity profiles, and traceability.
- Regulated commercialization: customers typically access the brand supply chain or qualified API-to-finished-product development route.
What can be stated as “supplier lists” from available public information?
A complete, accurate “supplier list” for verteporfin requires a verifiable mapping of:
- specific named verteporfin manufacturers (API and/or finished product),
- their product forms (API, intermediate, finished drug),
- their regulatory status (marketing authorization involvement vs research chemical sales),
- and documentation that they supply verteporfin under their own catalog or manufacturing role.
In this environment, no verteporfin supplier roster with verifiable names and roles is present in the provided context, and there is no source material here to cite. Under strict data-integrity rules, a supplier list cannot be produced without citations to named suppliers and their supply role.
Because the prompt provides only the target molecule (“verteporfin”) and not any supplier candidates or sources, producing a factual supplier list would require uncited external assumptions, which would be noncompliant.
Key Takeaways
- Verteporfin supply splits into finished product distribution and API chemical supply.
- Supplier identification is role-dependent: brand channel for regulated ophthalmology vs API manufacturers for clinical manufacturing vs specialty distributors for research-grade use.
- A factual, names-and-roles supplier list cannot be produced from the provided information without verifiable, citable supplier identities.
FAQs
-
Is verteporfin supplied mainly as an API or as a finished drug?
Finished product supply dominates in regulated ophthalmology use; API supply is typical for clinical manufacturing and research.
-
Do research-grade verteporfin suppliers differ from GMP API suppliers?
Yes. Research-grade suppliers usually provide COAs suited to lab use, while GMP API suppliers provide higher documentation and tighter specification control.
-
Who supplies verteporfin in photodynamic therapy programs?
Programs typically source either branded finished product via commercial distribution or API through qualified manufacturing supply chains.
-
What determines which supplier a company should use?
The intended regulatory pathway and manufacturing needs: research methods, clinical GMP, or commercialization-grade supply.
-
Can the supplier list be generalized across regions?
No. Distribution depends on marketing authorization structures, importer networks, and qualified supply agreements per region.
References
[1] (No cited sources were provided in the prompt.)
